# Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

> **NCT00867061** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Traws Pharma, Inc.**

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** ON 01910.Na Concentrate

## Key facts

- **NCT ID:** NCT00867061
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Mutual decision by site and sponsor because of difficulty recruiting Patients.
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00867061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00867061, "Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00867061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*